Claims for Patent: 7,968,735

Summary for Patent: 7,968,735

Title:	Light-emitting biomarker
Abstract:	The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical or biological, in particular enzymatic, phenomenon, as well as a kit for implementing said method.
Inventor(s):	Renard; Pierre-Yves (Paris, FR), Romieu; Anthony (Rouen, FR), Massonneau; Marc (Tillieres sur Avre, FR)
Assignee:	Quidd (Mont-Saint-Aignan, FR) Universite de Rouen (Mont-Saint-Aignan, FR)
Application Number:	11/920,982
Patent Claims:	1. A compound of general formula (I): S--B-A in which: S represents a labile structure that can be activated by a biological entity, and S having the general formula (VI): P-L-.quadrature. in which: .quadrature. symbolizes a covalent bond with B; P represents a substrate that can be recognized by the biological entity; and L represents an oxygen, sulfur, nitrogen, carbonyl or a --CO-Q- functional group, with Q being O, S or NH; B is a reactive branch, of which the chemical structure is such that the activation of the labile structure S induces intramolecular rearrangement in a suitable form for releasing a molecule A.sup.-; and B having the general formula (III): ##STR00015## in which: .quadrature. and .diamond. symbolize, respectively, a covalent bond with the labile structure S and a chromophore A; j is an integer ranging from 0 to 2; R.sub.4 is a C.sub.1-C.sub.20 hydrocarbon-based chain, where appropriate interrupted by one or more heteroatoms and/or space --CO and/or --N(alkyl)-unit(s), located ortho, meta or para to the .quadrature.-(CH.sub.2).sub.j-radical, and chosen from --(CH.sub.2).sub.k-.diamond., --(CH.sub.2).sub.k--C(O)-.diamond., and --CH.sub.2--O--C(O)--N(CH.sub.3)--(CH.sub.2).sub.2--N(CH.sub.3)--C(O)-.di- amond. radicals, with k being equal to 1 or 2; R.sub.5 and R.sub.6 are, independently of one another, a hydrogen atom or a saturated or unsaturated, linear, branched or cyclic, C.sub.1-C.sub.20 hydrocarbon-based chain chosen from an alkyl radical, an alkoxy radical, an alkylamino or dialkylamino radical, an alkylthio and a C.sub.6-C.sub.30 aromatic ring chosen from an aryl radical, an aryloxy radical, an arylamino radical and an arylthio radical A is a chromophore of formula (IIa): ##STR00016## in which: .diamond. symbolizes the covalent bond with B; R.sub.1 is a saturated or unsaturated, linear, branched or cyclic, C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 alkoxy radical, optionally comprising one or more atoms chosen from O, N and S, and is optionally substituted; R.sub.2 and R.sub.3 are linked to form a spiro adamantyl radical with the carbon of the dioxetane ring which bears R.sub.2 and R.sub.3 substituted where appropriate; Ar represents a C.sub.6-C.sub.30 arylene radical of general formula (IVa): ##STR00017## in which: .DELTA. symbolizes a covalent bond with X and * symbolizes a covalent bond with the dioxetane ring; R.sub.10 represents a hydrogen atom, an electroactive radical or a fluorescent radical; and R.sub.11 is chosen from a hydrogen atom and a C.sub.6-C.sub.10 aryl radical fused with the phenylene radical, and X represents O, NH or S; and derivatives thereof. 2. The compound as claimed in claim 1, wherein R.sub.1 is a fluorescent radical. 3. The compound as claimed in claim 1, wherein R.sub.1 is a fluorescent radical, it is chosen from phenyl and its derivatives, naphthalene and its derivatives, anthracene and its derivatives, pyrene and its derivatives, biphenyl and its derivatives, acridine and its derivatives, coumarin and its derivatives, xanthene and its derivatives, phthalocyanine and its derivatives, stilbene and its derivatives, furan and its derivatives, oxazole and its derivatives, oxadiazole and its derivatives, nitrobenzoxadiazole and its derivatives, benzothiazole and its derivatives, fluorescein and its derivatives, rhodamine and its derivatives, BODIPY and its derivatives, eosin and its derivatives, erythrosine and its derivatives, resorufin and its derivatives, quinoline and its derivatives, carbazole and its derivatives, fluorescent cyanines and derivatives, carbocyanine and its derivatives, pyridinium salts and derivatives, a fluorescent complex of lanthanides and its derivatives, fluorescent proteins and quantum dots. 4. The compound as claimed in claim 1, wherein R.sub.1 and/or R.sub.10 is a fluorescent radical chosen from phenyl and its derivatives, naphthalene and its derivatives, anthracene and its derivatives, pyrene and its derivatives, biphenyl and its derivatives, acridine and its derivatives, coumarin and its derivatives, xanthene and its derivatives, phthalocyanine and its derivatives, stilbene and its derivatives, furan and its derivatives, oxazole and its derivatives, oxadiazole and its derivatives, nitrobenzoxadiazole and its derivatives, benzothiazole and its derivatives, fluorescein and its derivatives, rhodamine and its derivatives, BODIPY and its derivatives, eosin and its derivatives, erythrosine and its derivatives, resorufin and its derivatives, quinoline and its derivatives, carbazole and its derivatives, fluorescent cyanines and derivatives, carbocyanine and its derivatives, pyridinium salts and derivatives, a fluorescent complex of lanthanides and its derivatives, fluorescent proteins and quantum dots. 5. The compound as claimed in claim 1, wherein R.sub.10 is an electroactive radical chosen from a halogen atom, a cyano radical, a nitro radical, a monosubstituted or disubstituted amide radical, an alkyl radical, an alkoxy radical, a trialkylammonium radical, an alkylamido radical, an alkylcarbamoyl radical, an ester radical, an alkylsulfonamido radical, a trifluoromethyl radical, an alkylsilyl, dialkylsilyl or trialkylsilyl radical, an alkylsiloxy, dialkylsiloxy or trialkylsiloxy radical, an alkylamidosulfonyl radical, an alkylsulfonyl radical, an alkyl thioether radical, a haloalkyl radical, a C.sub.6-C.sub.10 radical chosen from an aryloxy radical, an arylamido radical, an arylcarbamoyl radical, an arylsulfonamido radical, an aryl radical, a heteroaryl radical, a triaryl or alkylarylsilyl radical, a triarylsiloxy radical, an arylamidosulfonyl radical, an arylsulfonyl radical and an aryl thioether radical. 6. The compound as claimed in claim 1, wherein X represents O. 7. The compound as claimed in claim 1, wherein the compound has the formula (Va): ##STR00018## 8. The compound as claimed in claim 1, wherein the compound has the formula (Vb): ##STR00019## 9. The compound as claimed in claim 8, wherein R.sub.10.dbd.R.sub.11.dbd.H, R.sub.1.dbd.R.sub.5.dbd.R.sub.6=--O--CH.sub.3, and R.sub.2 and R.sub.3 are linked to form a spiro adamantyl radical with the carbon of the dioxetane ring which bears R.sub.2 and R.sub.3, substituted where appropriate. 10. The compound as claimed in claim 1, wherein S represents a structure that is labile by action of an enzyme. 11. The compound as claimed in claim 10, wherein S represents a structure that is labile by action of a protease, L represents --CO-Q, with Q being NH, and P represents a substrate recognized by the protease. 12. The compound as claimed in claim 1, wherein it is a derivative of formula (VII): D-S--B-A in which: D represents a target structure. 13. The compound as claimed in claim 12, wherein the target structure D is chosen from a lectin, an antibody or a fragment of the antibody; a cell receptor ligand; a ligand capable of interacting with a membrane lipid or phospholipid; and a ligand capable of interacting with a sugar present at the surface of cells. 14. A pharmaceutical composition comprising at least an effective amount of at least one compound as defined in claim 1. 15. A method for detecting and/or quantifying a biological entity, using at least one compound as claimed in claim 1, in which S represents a labile structure that can be activated by the entity. 16. A method for detecting and/or quantifying a biological entity comprising at least the steps of: bringing at least an effective amount of at least one compound as defined in claim 1 in which S represents a labile structure that can be activated by said biological entity to be detected and/or quantified, into contact with a medium assumed to comprise said entity; and measuring the luminescent signal generated. 17. The method as claimed in claim 16, wherein the compound is: ##STR00020## 18. The method as claimed in claim 16, carried out in vitro comprising the step of adding a light amplifier chosen from fluorescein, bovine albumin, human albumin, polymeric quaternary onium salts, a sodium salt of fluorescein, and poly(benzyltributyl)ammonium. 19. The method as claimed in claim 16, wherein the biological entity to be detected and/or quantified is an enzyme and wherein S in the compound of general formula (I) represents a substrate that can be activated by the enzyme. 20. A kit for the detection and/or quantification via detection of a biological entity comprising at least one compound as defined in claim 1, in which S represents a labile structure that can be activated by said biological entity to be detected and/or quantified. 21. The diagnostic method in vivo using a pharmaceutical composition comprising a compound as defined in claim 1. 22. The compound as claimed in claim 1, wherein R.sub.2 and R.sub.3 are substituted by radicals R.sub.8 and/or R.sub.9, wherein R.sub.8 and R.sub.9 are, independently of one another, an electroactive radical chosen from a hydroxyl radical, a halogen atom, a cyano radical, an amide radical, an alkoxy radical, a haloalkyl radical, a phenyl radical and an alkoxyphenyl radical. 23. The method as claimed in claim 18, wherein the polymeric quaternary onium salts are chosen from poly(vinylbenzyltrimethyl)ammonium chloride (TMQ), poly(vinylbenzyltributyl)ammonium chloride (TBQ), poly(vinylbenzyldimethyl)ammonium chloride (BDMQ), poly(vinylbenzyltributyl)phosphonium chloride, poly(vinylbenzyltributyl)sulfonium chloride, and poly(benzyldimethylvinylbenzyl)ammonium chloride.

Details for Patent 7,968,735

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2025-05-27
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2025-05-27
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2025-05-27
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2025-05-27
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2025-05-27
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2025-05-27